Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Should Look Through IIRIS To Improve Science, Panel Says; Funding Is Worry

Executive Summary

Increasing developments in emerging sciences, such as personalized medicine, could reach roadblocks at FDA where limited resources for specialized personnel and advanced equipment may inhibit research, a report from FDA's Science Board's Subcommittee on Science and Technology shows

You may also be interested in...



FDA Science Board's Report: Legislative Negotiating Tactic, Or Just Whining For Money?

21st Century Cures criticized by FDA advisors for unfunded mandates, but legislation also represents best near-term prospect for reforms of the kind the report envisions.

Hamburg’s Departure Hinged On Selection Of FDA Leadership Team

Medical countermeasures expert Luciana Borio moves to chief scientist role; Hamburg offers preview of the leadership approaches of Stephen Ostroff and Robert Califf.

FDA Workforce Challenges Include Long Hiring Cycle, Large Temporary Staff

A report on the state of FDA’s workforce finds that eight of 10 medical offices are temporary or term appointed and that it takes about six months to bring a new employee onboard. FDA’s new Office of Human Resources is seeking to reduce the time-to-hire.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS049097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel